Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT02290717

Fractional Laser in Combination With UVB Therapy in Vitiligo Patients

Fractional Laser Abrasion in Combination With UVB Therapy in Vitiligo Patients: a Randomized Controlled Study.

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Netherlands Institute for Pigment Disorders · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Rationale: Vitiligo is a common skin disorder that can impair a patient's quality of life. Many depigmented lesions in vitiligo patients remain therapy resistant for medical treatment. Therefore new therapeutic options in these patients are necessary. Currently, dermabrasion by conventional or fractional laser therapy in combination with NB-UVB therapy and steroids appears to be effective in therapy resistant areas. However, little literature on this combination is available. Objectives: To assess the efficacy and patient safety of (1)fractional CO2-laser treatment in combination with NB- UVB,(2) fractional CO2-laser treatment in combination with NB- UVB and topical corticosteroids versus NB-UVB treatment alone(3) Study design: Prospective observer blinded randomised intra-patient controlled study. Study population: 23 patients ≥ 18 years with non segmental vitiligo who receive NB-UVB treatment at the Netherlands Institute for Pigment Disorders (SNIP) at the Academic Medical Centre University of Amsterdam. We will include patients with 3 depigmented lesions that are resistant to NB- UVB treatment after 3 to 6 months. Methods: Three NB-UVB resistant depigmented regions on the trunk or extremities will be randomly allocated to;(1) NB-UVB treatment in combination with fractional CO2 laser abrasion, or (2) NB-UVB treatment in combination with fractional CO2 laser abrasion and topical steroids, or (3) NB-UVB treatment alone. NB-UVB treatment and topical steroids will be given according to the standard treatment protocol of the SNIP and continued for at least 6 months. Two and 6 months after the laser treatment, the percentage of repigmentation of the lesions will be assessed.

Conditions

Interventions

TypeNameDescription
DEVICEFractional CO2 laser
OTHERNB-UVB therapyNB-UVB therapy (according to the standard treatment protocol of the SNIP, which the patient is already been treated with) will be continued for both treated and control sites during 6 months.
DRUGFluticasone Propionate Cream 0.05%4 times a week (standard IPD protocol)

Timeline

Start date
2015-05-01
Primary completion
2015-11-01
Completion
2015-11-01
First posted
2014-11-14
Last updated
2016-04-18

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT02290717. Inclusion in this directory is not an endorsement.